AstraZeneca: license agreement between Alexion and Neurimmune


(CercleFinance.com) – Alexion, AstraZeneca’s rare disease subsidiary, announced on Friday the signing of an exclusive licensing agreement with Swiss biopharmaceutical company Neurimmune.

Under the agreement, Alexion will obtain worldwide rights to develop, manufacture and market NI006, a monoclonal antibody currently in development.

This product is currently the subject of a Phase Ib study in the treatment of cardiac transthyretin amyloidosis, a rare and underdiagnosed disease which limits the life expectancy of patients to four years after their diagnosis.

NI006 targets abnormal changes in the transthyretin protein (TTR), which helps remove amyloid deposits that build up in the heart and lead to progressive cardiac dysfunction.

Alexion will make an upfront payment of $ 30 million to Neurimmune, an amount that could be accompanied by future milestone payments of up to $ 730 million, not including royalties that could be paid if the program is approved. processing.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.

Facebook
Linkedin
E-mail





Source link -85